title: Novel non-AR therapeutic targets in castrate resistant prostate cancer.
abstract: Castrate resistant prostate cancer (CRPC) remains a disease with significant morbidity and mortality. The recent approval of abiraterone and enzalutamide highlight the improvements which can be made targeting the androgen receptor (AR) axis. Nonetheless, resistance inevitably develops and there is continued interest in targeting alternate pathways which cause disease resistance and progression. Here, we review non-AR targets in CRPC, with an emphasis on novel agents now in development. This includes therapeutics which target the tumour microenvironment, the bone metastatic environment, microtubules, cellular energetics, angiogenesis, the stress response, survival proteins, intracellular signal transduction, DNA damage repair and dendritic cells. Understanding the hallmarks of prostate cancer resistance in CRPC has led to the identification and development of these new targets. We review the molecular rationale, as well at the clinical experience for each of these different classes of agents which are in clinical development.
authors.affiliation: Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Toren
authors.affiliation: Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Martin E
authors.initials: ME
authors.lastname: Gleave
keywords: Androgen receptor (AR); abiraterone; castrate resistant prostate cancer (CRPC); non-AR therapeutic targets
references.citation: J Clin Oncol. 2005 Dec 1;23(34):8724-9
references.pmid: 16314632
references.citation: Expert Opin Investig Drugs. 2013 May;22(5):635-61
references.pmid: 23586879
references.citation: Cancer Res. 2012 Nov 1;72 (21):5588-99
references.pmid: 23118055
references.citation: Ann Oncol. 2012 Jan;23(1):53-8
references.pmid: 21765178
references.citation: J Clin Oncol. 2005 Mar 1;23(7):1439-46
references.pmid: 15735119
references.citation: Curr Cancer Drug Targets. 2007 Sep;7(6):591-604
references.pmid: 17896924
references.citation: N Engl J Med. 2004 Oct 7;351(15):1502-12
references.pmid: 15470213
references.citation: Cancer Res. 2009 Nov 1;69(21):8386-94
references.pmid: 19826044
references.citation: J Cell Physiol. 2011 Nov;226(11):2762-81
references.pmid: 21302297
references.citation: J Clin Oncol. 2008 Jan 10;26(2):242-5
references.pmid: 18182665
references.citation: Semin Cell Dev Biol. 2010 Feb;21(1):2-10
references.pmid: 19840860
references.citation: Curr Drug Targets. 2011 Apr;12(4):563-78
references.pmid: 21226671
references.citation: EMBO Mol Med. 2009 Sep;1(6-7):315-22
references.pmid: 20049735
references.citation: Semin Oncol. 1993 Jun;20(3 Suppl 2):38-43
references.pmid: 7684865
references.citation: Cancer Res. 2007 Nov 1;67(21):10455-65
references.pmid: 17974989
references.citation: Cancer. 2011 May 15;117(10):2077-85
references.pmid: 21523719
references.citation: N Engl J Med. 2012 Jun 28;366(26):2443-54
references.pmid: 22658127
references.citation: Br J Cancer. 2010 Feb 16;102(4):678-84
references.pmid: 20104229
references.citation: Cancer Res. 2010 Oct 15;70(20):7992-8002
references.pmid: 20807808
references.citation: Cell Death Differ. 2006 Jan;13(1):12-9
references.pmid: 16179938
references.citation: Urology. 2004 May;63(5):940-5
references.pmid: 15134985
references.citation: BJU Int. 2008 Aug;102(3):389-97
references.pmid: 18336596
references.citation: N Engl J Med. 2012 Sep 27;367(13):1187-97
references.pmid: 22894553
references.citation: Cancer Res. 2013 Aug 15;73(16):5206-17
references.pmid: 23786771
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7421-8
references.pmid: 19920114
references.citation: Bioorg Med Chem Lett. 2012 Jan 15;22(2):806-10
references.pmid: 22217877
references.citation: Cancer. 2012 Jan 1;118(1):63-71
references.pmid: 21976132
references.citation: Cancer Res. 2006 Apr 15;66(8):4419-25
references.pmid: 16618768
references.citation: Ann Oncol. 2007 Nov;18(11):1765-73
references.pmid: 17426060
references.citation: N Engl J Med. 2004 Oct 7;351(15):1513-20
references.pmid: 15470214
references.citation: Lancet. 2010 Oct 2;376(9747):1147-54
references.pmid: 20888992
references.citation: Proc Natl Acad Sci U S A. 1988 Jun;85(11):3762-6
references.pmid: 2897689
references.citation: Lancet. 2012 Jan 7;379(9810):39-46
references.pmid: 22093187
references.citation: Oncogene. 2008 Dec;27 Suppl 1:S149-57
references.pmid: 19641500
references.citation: Cell Signal. 2007 Dec;19(12 ):2487-97
references.pmid: 17826033
references.citation: PLoS One. 2012;7(12):e51189
references.pmid: 23300537
references.citation: Int J Biochem Cell Biol. 2012 Oct;44(10):1646-56
references.pmid: 22571949
references.citation: Nat Genet. 2010 Aug;42(8):668-75
references.pmid: 20601956
references.citation: J Nucl Med. 2002 Sep;43(9):1150-6
references.pmid: 12215552
references.citation: Lancet Oncol. 2007 Jul;8(7):587-94
references.pmid: 17544845
references.citation: J Urol. 2002 Jul;168(1):9-12
references.pmid: 12050481
references.citation: Expert Opin Pharmacother. 2011 Apr;12(6):977-82
references.pmid: 21406025
references.citation: J Chemother. 2004 Nov;16 Suppl 4:83-5
references.pmid: 15688618
references.citation: Oncol Lett. 2010 Mar;1(2):319-325
references.pmid: 22966302
references.citation: Urol J. 2007 Spring;4(2):95-100
references.pmid: 17701929
references.citation: Cancer Res. 2010 Mar 15;70(6):2307-17
references.pmid: 20197463
references.citation: Cancer Causes Control. 2009 Nov;20(9):1617-22
references.pmid: 19653109
references.citation: Eur Urol. 2013 Apr;63(4):709-16
references.pmid: 23287698
references.citation: Expert Opin Investig Drugs. 2011 Dec;20(12):1677-84
references.pmid: 22035268
references.citation: Clin Cancer Res. 2010 Apr 1;16(7):2115-21
references.pmid: 20215531
references.citation: Cancer Biol Ther. 2012 Feb 1;13(3):123-9
references.pmid: 22236832
references.citation: Oncogene. 2004 Mar 18;23(12):2197-205
references.pmid: 14767470
references.citation: Ann Oncol. 2009 Jul;20(7):1264-9
references.pmid: 19297314
references.citation: Prostate. 2012 Nov;72(15):1638-47
references.pmid: 22457212
references.citation: Clin Cancer Res. 2005 May 15;11(10):3854-61
references.pmid: 15897586
references.citation: Curr Oncol. 2011 Jun;18(3):e150-7
references.pmid: 21655153
references.citation: Cancer Biother Radiopharm. 2010 Dec;25(6):601-13
references.pmid: 21204754
references.citation: Mol Pharmacol. 2001 Dec;60(6):1296-307
references.pmid: 11723237
references.citation: Cancer Cell. 2010 Jul 13;18(1):11-22
references.pmid: 20579941
references.citation: Am J Epidemiol. 2008 Oct 15;168(8):925-31
references.pmid: 18700234
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1629-37
references.pmid: 20484016
references.citation: Mol Cancer Ther. 2008 Jan;7(1):121-32
references.pmid: 18202015
references.citation: Cancer Res. 1992 Dec 15;52(24):6940-4
references.pmid: 1458483
references.citation: N Engl J Med. 2011 May 26;364(21):1995-2005
references.pmid: 21612468
references.citation: J Natl Cancer Inst. 2004 Jun 2;96(11):879-82
references.pmid: 15173273
references.citation: Neoplasia. 2013 Jul;15(7):761-72
references.pmid: 23814488
references.citation: Eur Urol. 2012 Feb;61(2):290-306
references.pmid: 22001436
references.citation: Urology. 2012 Mar;79(3):644-9
references.pmid: 22386418
references.citation: Curr Opin Urol. 2013 May;23(3):189-93
references.pmid: 23385974
references.citation: Cancer Res. 2007 Jan 15;67(2):511-9
references.pmid: 17234758
references.citation: N Engl J Med. 2013 Jan 10;368(2):138-48
references.pmid: 23228172
references.citation: Nat Rev Cancer. 2002 May;2(5):389-96
references.pmid: 12044015
references.citation: Urol Clin North Am. 2012 Nov;39(4):517-31
references.pmid: 23084528
references.citation: Clin Cancer Res. 2011 Sep 1;17(17):5765-73
references.pmid: 21788353
references.citation: Eur J Cancer. 1991;27(8):954-8
references.pmid: 1716935
references.citation: Lancet. 2011 Mar 5;377(9768):813-22
references.pmid: 21353695
references.citation: Eur J Cancer. 2010 Jul;46(10):1770-2
references.pmid: 20483588
references.citation: J Clin Oncol. 2011 Oct 20;29(30):4022-8
references.pmid: 21931019
references.citation: Mol Cancer Ther. 2003 Jul;2(7):597-605
references.pmid: 12883031
references.citation: Mol Cancer Ther. 2013 Nov;12(11):2342-55
references.pmid: 23966621
references.citation: J Clin Oncol. 2013 Sep 1;31(25):3069-75
references.pmid: 23918942
references.citation: IUBMB Life. 2003 Dec;55(12):661-8
references.pmid: 14769002
references.citation: J Clin Oncol. 2013 Feb 1;31(4):412-9
references.pmid: 23169517
references.citation: World J Urol. 2005 Feb;23(1):38-46
references.pmid: 15770517
references.citation: Eur Urol. 2013 Feb;63(2):189-97
references.pmid: 23000088
references.citation: Urol Oncol. 2009 Jan-Feb;27(1):48-52
references.pmid: 19111798
references.citation: Cancer Cell. 2011 May 17;19(5):575-86
references.pmid: 21575859
references.citation: N Engl J Med. 2010 Jul 29;363(5):411-22
references.pmid: 20818862
references.citation: Cancer Res. 2013 Feb 15;73(4):1386-99
references.pmid: 23149916
references.citation: Clin Cancer Res. 2004 Aug 1;10(15):5048-57
references.pmid: 15297406
references.citation: Cancer. 2006 Jan 1;106(1):58-62
references.pmid: 16329138
references.citation: Traffic. 2007 May;8(5):554-65
references.pmid: 17451556
references.citation: Cancer Discov. 2011 Nov;1(6):487-95
references.pmid: 22389870
references.citation: Nat Rev Urol. 2013 Aug;10(8):441-51
references.pmid: 23857181
references.citation: Int J Cancer. 2013 Oct 15;133(8):1955-66
references.pmid: 23564295
references.citation: J Clin Oncol. 2003 Sep 1;21(17):3335-42
references.pmid: 12947070